Palvella获FDA优先审评资格，核心资产迎来关键进展 (PVLA:NASDAQ)
· seekingalpha.com
Palvella Therapeutics (PVLA) 股价上涨，因公司核心资产Qtorin rapamycin的上市申请获得FDA优先审评资格。点击此处了解更多。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...